$161.78 Million in Sales Expected for Repligen Co. (NASDAQ:RGEN) This Quarter

Wall Street analysts forecast that Repligen Co. (NASDAQ:RGEN) will announce $161.78 million in sales for the current quarter, according to Zacks. Seven analysts have made estimates for Repligen’s earnings. The highest sales estimate is $166.80 million and the lowest is $144.40 million. Repligen posted sales of $94.06 million during the same quarter last year, which suggests a positive year-over-year growth rate of 72%. The business is scheduled to issue its next quarterly earnings report on Thursday, November 4th.

On average, analysts expect that Repligen will report full-year sales of $632.54 million for the current fiscal year, with estimates ranging from $577.30 million to $644.90 million. For the next financial year, analysts anticipate that the company will report sales of $751.07 million, with estimates ranging from $725.00 million to $790.10 million. Zacks Investment Research’s sales averages are an average based on a survey of research analysts that that provide coverage for Repligen.

Repligen (NASDAQ:RGEN) last issued its earnings results on Monday, July 26th. The biotechnology company reported $0.79 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.52 by $0.27. Repligen had a net margin of 19.65% and a return on equity of 9.21%. The firm had revenue of $162.96 million during the quarter, compared to analysts’ expectations of $144.24 million. During the same quarter last year, the company posted $0.42 earnings per share. The firm’s revenue was up 86.3% compared to the same quarter last year.

RGEN has been the subject of several recent research reports. KeyCorp raised their target price on shares of Repligen from $255.00 to $335.00 and gave the stock an “overweight” rating in a report on Friday, September 17th. Stephens raised their price target on shares of Repligen from $255.00 to $290.00 and gave the company an “overweight” rating in a research report on Friday, August 20th. Finally, Craig Hallum raised their price target on shares of Repligen from $251.00 to $258.00 and gave the company a “buy” rating in a research report on Wednesday, July 28th. One research analyst has rated the stock with a hold rating and five have given a buy rating to the company’s stock. Based on data from MarketBeat, Repligen presently has a consensus rating of “Buy” and an average target price of $262.17.

Shares of Repligen stock traded down $0.95 during trading on Friday, hitting $323.26. 341,141 shares of the company’s stock were exchanged, compared to its average volume of 384,809. The business has a 50-day simple moving average of $266.43 and a 200-day simple moving average of $219.79. Repligen has a 52-week low of $138.63 and a 52-week high of $327.32. The stock has a market capitalization of $17.75 billion, a price-to-earnings ratio of 180.59 and a beta of 0.90.

In other news, Director Thomas F. Ryan, Jr. sold 780 shares of Repligen stock in a transaction dated Wednesday, August 4th. The shares were sold at an average price of $250.50, for a total value of $195,390.00. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Director Karen A. Dawes sold 4,585 shares of Repligen stock in a transaction dated Tuesday, July 20th. The shares were sold at an average price of $202.09, for a total transaction of $926,582.65. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 52,154 shares of company stock worth $14,144,680. 1.20% of the stock is owned by company insiders.

Several large investors have recently bought and sold shares of RGEN. RPg Family Wealth Advisory LLC purchased a new position in shares of Repligen in the second quarter worth about $27,000. Creative Financial Designs Inc. ADV lifted its stake in shares of Repligen by 50.0% in the second quarter. Creative Financial Designs Inc. ADV now owns 150 shares of the biotechnology company’s stock worth $30,000 after buying an additional 50 shares in the last quarter. Itau Unibanco Holding S.A. purchased a new position in shares of Repligen in the second quarter worth about $37,000. Institutional & Family Asset Management LLC lifted its stake in shares of Repligen by 1,900.0% in the first quarter. Institutional & Family Asset Management LLC now owns 200 shares of the biotechnology company’s stock worth $39,000 after buying an additional 190 shares in the last quarter. Finally, Rational Advisors LLC purchased a new position in shares of Repligen in the second quarter worth about $48,000. 83.82% of the stock is currently owned by hedge funds and other institutional investors.

About Repligen

Repligen Corp. provides bioprocessing technologies and solutions used in the process of manufacturing biologic drugs. It serves through the following product lines: Chromatography, Filtration and OEM Products (Proteins). The Chromatography product line includes a number of products used in the downstream purification and quality control of biological drugs.

Featured Story: Technical Analysis

Get a free copy of the Zacks research report on Repligen (RGEN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Repligen (NASDAQ:RGEN)

Receive News & Ratings for Repligen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repligen and related companies with MarketBeat.com's FREE daily email newsletter.